Skip to main content

Table 3 Results of deterministic sensitivity analysis

From: Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy

Input

Δ Costs

(€)

Δ LY

Δ QALY

ICER

(€/LY)

ICUR

(€/QALY)

Base case scenario

3549

0.475

0.384

7473

9246

Model settings

 Discount rate 0%

3733

0.494

0.399

7551

9347

 Discount rate 5%

3436

0.463

0.374

7423

9181

 Time horizon 28 days

− 666,50

0.000

0.002

Dominant

Dominant

 Time horizon 1 year

717

0.164

0.135

4384

5316

 Alternative patients’ demographic characteristics*

3247

0.433

0.350

7491

9269

 Utility Values + 20%

3549

0.475

0.457

7473

7758

 Utility Values −20%

3549

0.475

0.307

7473

11,558

Calibration of effectiveness

 Long-term care (50%)

9499

0.475

0.356

20,004

26,691

 Mortality after 28 days + 20%

3025

0.423

0.342

7154

8833

 Mortality after 28 days −20%

4150

0.535

0.431

7762

9622

Calibration of costs

 Hospitalisation costs € 4981.23

2878

0.475

0.384

6061

7500

 RRT costs + 20%

3697

0.475

0.384

7786

9634

 RRT costs −20%

3400

0.475

0.384

7160

8859

 Vials sharing

3784

0.475

0.384

7968

9859

 Follow-up costs after home discharge € 87.41

3560

0.475

0.384

7497

9276

  1. *Patients with an average age of 68.0 years and predominantly male (63.1%) [34]
  2. BAT: best available therapy; ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; LY: life years; QALY: quality assisted life years; RRT: renal replacement therapy